Abstract
Purpose
To evaluate the efficacy and tolerability of topiramate (TPM) as monotherapy for patients with temporal lobe epileptic seizures based on an observational study.
Methods
We evaluated 41 patients (20 female, mean age 54+18 years) with temporal lobe epilepsy (TLE) referred to the Epilepsy Unit, University of Catanzaro, Italy. Patients received TPM as monotherapy directly or after having taken other antiepileptic drugs. Seizure frequency changes and adverse events were recorded. Follow-up was conducted for a period of at least two years after treatment.
Results
Patients received TPM, 50–600 mg/day, de novo (n=29) or initially as add-on therapy before the switch (n=12). In total, 28 of 41 patients achieved seizure freedom, whereas 10 showed a ≥50% reduction of seizure frequency. Two patients did not respond well and one patient discontinued TPM due to adverse effects.
Conclusions
Our results confirm that TPM as either monotherapy or add-on therapy at doses of 50–600 mg/day effectively reduces seizure frequency in TLE. TPM is particular effective and very well tolerated in patients with mild TLE.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Aguglia U, Gambardella A, Le Piane E, et al. Mild non-lesional temporal lobe epilepsy. a common unrecognized disorder with onset in adulthood. Can J Neurol Sci 1998; 25: 282–286.
Andreou AP, Goadsby PJ. Topiramate in the treatment of migraine: a kainite glutamate receptor antagonist within the trigeminothalamic pathway. Cephalgia 2011; 31: 1343–1358.
Artinian J, Peret A, Marti G, Epsztein J, Crépel V. Synaptic kainite receptors in interplay with INA shift the sparse firing of dentate granule cells to a sustained rhythmic mode in temporal lobe epilepsy. J Neurosci 2011; 31: 10811–10818.
Bergey GK. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia 2005; 46: 161–168.
Commission on Classification Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389–399.
El Yaman SH, Mroueh SM, Sinno DD, Mikati MA. Long-term patterns of weight changes during topiramate therapy: an observational study. Neurology 2007; 69: 310–311.
Gambardella A, Pucci F, La Piane E, et al. Usefulness of latero-orbital electrodes in detecting interictal epileptiform activity-a study of 60 patients with complex partial seizures. Electroencephalogr Clin Neurophysiol 1998; 107: 174–176.
Gambardella A, Manna I, Labate A, et al. GABA(B) receptor 1 polymorphism (G1465A) is associated with temporal lobe epilepsy. Neurology 2003; 60: 560–563.
Giannakodimos ST, Georgiadis G, Tsounis ST, et al. Addon topiramate in the treatment of refractory partial-onset epilepsy: clinical experience of outpatient epilepsy clinics from 11 general hospitals. Seizure 2005; 14: 396–402.
Glauser TA, Levisohn PM, Ritter F, Sachdeo RC. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia 2000; 41: S86–S90.
Herrero AI, Del Olmo N, González-Escalada JR, Solís JM. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology 2002; 42: 210–220.
Jette N, Hemming K, Hutton JL, Marson AG. Topiramate addon for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2008; 3: CD001417.
Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004; 46: 1097–1104.
Labate A, Ventura P, Gambardella A, et al. MRI evidence of mesial temporal sclerosis in sporadic “benign” temporal lobe epilepsy. Neurology 2006; 66: 562–565.
Labate A, Cerasa A, Gambardella A, Aguglia U, Quattrone A. Hippocampal and thalamic atrophy in mild temporal lobe epilepsy: a VBM study. Neurology 2008; 71: 1094–1101.
Labate A, Gambardella A, Andermann E, et al. Benign mesial temporal lobe epilepsy. Nat Rev Neurol 2011; 7: 237–240.
Park HJ, Kim HJ, Park HJ, et al. Protective effect of topiramate on kainic acid-induced cell death in mice hippocampus. Epilepsia 2008; 49: 163–167.
Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia 1997; 38: 294–300.
Siniscalchi A, Gallelli L, De Sarro GB. Use of antiepileptic drugs for hyperkineticmovement disorders. Curr Neuropharmacol 2010; 8: 359–366.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Labate, A., Siniscalchi, A., Mumoli, L. et al. Topiramate and temporal lobe epilepsy: an open-label study. Epileptic Disord. 14, 163–166 (2012). https://doi.org/10.1684/epd.2012.0497
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/epd.2012.0497